2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

Psoriasis, lichen planus, and pityriasis rosea share overlapping presentations and comorbidities, but distinct pathophysiologies require accurate diagnosis and tailored therapeutic approaches.

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

Patient Care tapped the rich trove of research and expert perspectives from the Revolutionizing Atopic Dermatitis 2025 conference to create a snapshot of the AD care of the future.

The findings highlight rezpegaldesleukin's novel broad-based Treg mechanism, suggesting it may be a potent option with potential for disease modification in atopic dermatitis.